Keyphrases
Glycogen Storage Disease
60%
Empagliflozin
40%
Monitoring Metrics
23%
Neutropenia
23%
Benefit-risk Assessment
20%
Questionnaire Survey
20%
Repurposing
20%
Patient-reported Outcomes
20%
Value-based Care
20%
International Survey
20%
Continuous Glucose Monitoring
20%
Liver Glycogen
20%
Ketotic Hypoglycemia
20%
Retrospective Observational Study
20%
Single Center
20%
Caregivers
15%
Daily Life
10%
Social Life
10%
Associated Symptoms
10%
Quality of Life
10%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
10%
Netherlands
10%
Working Life
10%
Austria
10%
Cost Savings
10%
ARFID
10%
Quality of Life Improvement
8%
Granulocyte Colony-stimulating Factor (G-CSF)
8%
Health Systems
6%
Budget Impact Analysis
6%
Neutrophil Dysfunction
6%
Carer Perspectives
6%
Healthy Individuals
6%
Physical Performance
5%
Physical Work
5%
Time-to-treatment
5%
Number of Days
5%
Pediatric Patients
5%
Clinical Symptoms
5%
Patient Well-being
5%
Socio-economic Aspects
5%
Treatment Effect
5%
Integrated Practice Unit
5%
Information Technology Platform
5%
Online Questionnaire
5%
Treatment Duration
5%
New Treatment Options
5%
Overall Well-being
5%
Medical Outcomes
5%
Number of Hospitalization
5%
Medicine and Dentistry
Glycogen Storage Disease
100%
Patient-Reported Outcome
40%
Empagliflozin
40%
Hypoglycemia
40%
Disease
34%
Quality of Life
30%
Neutropenia
23%
Water-Electrolyte Imbalance
20%
Fatty Acid Oxidation
20%
Retrospective Study
20%
Reactive Attachment Disorder
20%
Observational Study
20%
Symptom
18%
Health Care Cost
16%
Sodium Glucose Cotransporter 2 Inhibitor
10%
Granulocyte Colony Stimulating Factor
8%
Wellbeing
8%
Patient Care
8%
Food Intake
6%
Rare Disease
6%
Healthcare Research
6%
Health Care
6%
Personal Value
6%
Neutrophil
6%
Physical Performance
5%
Pediatrics Patient
5%
Social Life
5%
Treatment Duration
5%
Treatment Effect
5%
Pharmacology, Toxicology and Pharmaceutical Science
Glycogen Storage Disease
100%
Hypoglycemia
44%
Empagliflozin
40%
Neutropenia
23%
Prospective Study
20%
Normal Human
20%
Repurposing
20%
Psychosocial Disorder
20%
Retrospective Study
20%
Observational Study
20%
Symptom
18%
Disease
14%
Sodium Glucose Cotransporter 2 Inhibitor
10%
Granulocyte Colony Stimulating Factor
8%
